WuXi Biologics Achieves Milestone in Biologics Manufacturing with WuXiUI™ Platform
WuXi Biologics has recently made a significant breakthrough in biologics manufacturing with the successful completion of 2,000L drug substance (DS) GMP production using its proprietary ultra-intensified fed-batch bioprocessing platform, WuXiUI™. This achievement marks a major milestone for the company, showcasing a 4-fold increase in productivity compared to traditional fed-batch methods.
By leveraging the advanced capabilities of WuXiUI™ and the proprietary platform cellular culture media MagniCHO™, WuXi Biologics was able to streamline the production process and significantly reduce overall production costs. The platform’s efficiency from mini scales to large-scale production demonstrates its maturity and effectiveness in enhancing the cost-effectiveness of biologics manufacturing.
The enhanced downstream processing capabilities enabled by WuXiUI™ resulted in doubled purification processing capacity and improved impurity removal, leading to a 50% reduction in downstream processing time and a final DS purity of 70%. Additionally, the platform enabled a 30-50% reduction in material and consumables usage, further contributing to cost savings and waste reduction.
The successful scale-up of the WuXiUI™ platform from bench scales to 2,000L GMP production confirms its robustness and readiness for larger-scale manufacturing. The platform’s performance was further enhanced by the integration of MagniCHO™, a proprietary platform cellular culture media enriched with nutrients for intensified processes.
Dr. Chris Chen, CEO of WuXi Biologics, highlighted the importance of technology innovation in accelerating biologics development and achieving cost efficiency for global clients. He emphasized the company’s commitment to enabling clients to bring high-quality biologics to market at affordable prices, ultimately benefiting patients worldwide.
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), continues to push the boundaries of biologics manufacturing with its cutting-edge technologies and expertise. With a strong focus on Environmental, Social, and Governance (ESG) responsibilities, the company strives to become a leader in sustainable biologics manufacturing.
In conclusion, WuXi Biologics’ achievement with the WuXiUI™ platform sets a new standard for biologics manufacturing efficiency and cost-effectiveness. As the company continues to innovate and improve its capabilities, it remains dedicated to providing high-quality biologics solutions to meet the growing demand in the market.